ES2403149T4 - Solvato acetónico de dimetoxi docetaxel y su procedimiento de preparación - Google Patents
Solvato acetónico de dimetoxi docetaxel y su procedimiento de preparación Download PDFInfo
- Publication number
- ES2403149T4 ES2403149T4 ES04787385T ES04787385T ES2403149T4 ES 2403149 T4 ES2403149 T4 ES 2403149T4 ES 04787385 T ES04787385 T ES 04787385T ES 04787385 T ES04787385 T ES 04787385T ES 2403149 T4 ES2403149 T4 ES 2403149T4
- Authority
- ES
- Spain
- Prior art keywords
- hydroxy
- acetone
- dimethoxy
- tax
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000012453 solvate Substances 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 15
- -1 dimethoxy docetaxel Chemical compound 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title claims description 4
- 229960003668 docetaxel Drugs 0.000 title description 3
- ZVAFCKLQJCZGAP-WDEREUQCSA-N (2r,3s)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H]([C@@H](O)C(O)=O)C1=CC=CC=C1 ZVAFCKLQJCZGAP-WDEREUQCSA-N 0.000 claims abstract description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000009331 sowing Methods 0.000 claims description 3
- 239000004593 Epoxy Substances 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epoxy Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0311016 | 2003-09-19 | ||
| FR0311016A FR2859996B1 (fr) | 2003-09-19 | 2003-09-19 | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| PCT/FR2004/002344 WO2005028462A1 (fr) | 2003-09-19 | 2004-09-16 | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2403149T3 ES2403149T3 (es) | 2013-05-14 |
| ES2403149T4 true ES2403149T4 (es) | 2013-06-24 |
Family
ID=34224354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES04787385T Expired - Lifetime ES2403149T4 (es) | 2003-09-19 | 2004-09-16 | Solvato acetónico de dimetoxi docetaxel y su procedimiento de preparación |
Country Status (37)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2001874A4 (en) * | 2006-03-21 | 2010-04-07 | Reddys Lab Ltd Dr | DOCETAXEL POLYMORPH AND CORRESPONDING METHODS |
| US7855591B2 (en) * | 2006-06-07 | 2010-12-21 | Atmel Corporation | Method and system for providing a charge pump very low voltage applications |
| US7652522B2 (en) * | 2006-09-05 | 2010-01-26 | Atmel Corporation | High efficiency low cost bi-directional charge pump circuit for very low voltage applications |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| FR2926551A1 (fr) * | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
| AU2013205442B2 (en) * | 2008-01-17 | 2016-05-12 | Aventis Pharma S.A. | Crystalline forms of dimethoxy docetaxel and methods for preparing same |
| EP2331140B1 (en) | 2008-08-11 | 2018-07-04 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
| FR2945211A1 (fr) * | 2009-05-06 | 2010-11-12 | Sanofi Aventis | Combinaison antitumorale comprenant la cabazitaxel et la capecitabine |
| CA2708489A1 (en) * | 2009-10-29 | 2011-04-29 | Aventis Pharma S.A. | Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer |
| WO2011051894A1 (en) | 2009-10-29 | 2011-05-05 | Aventis Pharma S.A. | Novel antitumoral use of cabazitaxel |
| AU2015200149B2 (en) * | 2009-10-29 | 2016-12-01 | Aventis Pharma S.A. | Novel antitumoral use of cabazitaxel |
| WO2012088445A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| CN103764637A (zh) * | 2011-04-12 | 2014-04-30 | 普拉斯化学品有限公司 | 卡巴他赛的固态形式及其制备方法 |
| WO2013024495A1 (en) * | 2011-08-18 | 2013-02-21 | Dr. Reddys Laboratories Limited | Pharmaceutical formulations of cabazitaxel |
| TWI526437B (zh) * | 2011-09-09 | 2016-03-21 | 台灣神隆股份有限公司 | 卡巴他賽之結晶型 |
| US8722900B2 (en) | 2011-10-31 | 2014-05-13 | Scinopharm Taiwan, Ltd. | Process for cabazitaxel, and intermediates thereof |
| CN103874692A (zh) | 2011-11-01 | 2014-06-18 | 费森尤斯卡比肿瘤学有限公司 | 卡巴他赛的无定形形式和用于其制备的方法 |
| ES2716799T3 (es) | 2011-11-28 | 2019-06-17 | Fresenius Kabi Oncology Ltd | Forma cristalina de cabazitaxel y proceso para la preparación de la misma |
| JP6025861B2 (ja) | 2011-12-13 | 2016-11-16 | アベンティス・ファーマ・ソシエテ・アノニム | カバジタキセルの結晶形およびこれを調製するための方法 |
| WO2013111157A1 (en) * | 2012-01-03 | 2013-08-01 | Shilpa Medicare Limited | Process for preparing amorphous cabazitaxel |
| SG11201404712UA (en) * | 2012-02-10 | 2014-09-26 | Aventis Pharma Sa | New pediatric uses of cabazitaxel |
| US9394266B2 (en) | 2012-03-08 | 2016-07-19 | IVAX International GmbH | Solid state forms of cabazitaxel and processes for preparation thereof |
| CN102675257B (zh) * | 2012-05-10 | 2014-07-02 | 上海金和生物技术有限公司 | 一种卡巴他赛晶体及其制备方法 |
| CN102746258B (zh) * | 2012-07-25 | 2015-02-04 | 重庆泰濠制药有限公司 | 卡巴他赛的结晶形式及其制备方法 |
| EP2880021A4 (en) | 2012-07-31 | 2015-06-17 | Yung Shin Pharm Ind Co Ltd | AMORPHIC CABACITAXEL |
| WO2014028704A1 (en) | 2012-08-15 | 2014-02-20 | Yung Shin Pharm. Ind. Co., Ltd. | Stable pharmaceutical formulation of cabazitaxel |
| CN103664836B (zh) * | 2012-09-20 | 2016-04-20 | 齐鲁制药有限公司 | 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法 |
| US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| CN103804323A (zh) * | 2012-11-14 | 2014-05-21 | 上海希迈医药科技有限公司 | 一种卡巴他赛溶剂化物及其制备方法和应用 |
| CN103058960B (zh) * | 2012-12-12 | 2014-12-10 | 江苏奥赛康药业股份有限公司 | 卡巴他赛多晶型形式及其制备方法 |
| EP2743264A1 (en) | 2012-12-13 | 2014-06-18 | INDENA S.p.A. | New crystalline form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof |
| CN103910698B (zh) * | 2012-12-30 | 2016-01-20 | 上海医药工业研究院 | 卡巴他赛丙酮合物及其结晶 |
| CN103910696B (zh) * | 2012-12-30 | 2016-01-20 | 上海医药工业研究院 | 卡巴他赛异丙醚合物及其结晶 |
| EP2777691A1 (en) | 2013-03-14 | 2014-09-17 | Pharmachemie B.V. | Taxoid - Purification of Liquid Excipients |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| WO2015000165A1 (zh) * | 2013-07-04 | 2015-01-08 | 北京新天宇科技开发有限公司 | 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法 |
| CN104277014A (zh) * | 2013-07-04 | 2015-01-14 | 北京新天宇科技开发有限公司 | 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法 |
| EP2865675A1 (en) | 2013-10-23 | 2015-04-29 | INDENA S.p.A. | A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof |
| EP2865674A1 (en) | 2013-10-23 | 2015-04-29 | INDENA S.p.A. | Crystalline solvate forms of Cabazitaxel |
| CN103601704B (zh) * | 2013-11-22 | 2015-05-06 | 石家庄智恒医药科技有限公司 | 无定形卡巴他赛的制备 |
| ES2904505T3 (es) | 2015-01-12 | 2022-04-05 | Emcure Pharmaceuticals Ltd | Formulación líquida de cabazitaxel |
| PL3258931T3 (pl) * | 2015-02-17 | 2020-12-28 | Erasmus University Medical Center Rotterdam | Zastosowanie kabazitakselu w leczeniu nowotworu złośliwego prostaty |
| EP3093014A1 (en) | 2015-05-13 | 2016-11-16 | Aventis Pharma S.A. | Cabazitaxel and its use for treating cancer |
| US10188626B2 (en) | 2015-11-03 | 2019-01-29 | Cipla Limited | Stabilized cabazitaxel formulations |
| CN116903624A (zh) | 2016-11-29 | 2023-10-20 | Ptc医疗Mp公司 | 墨蝶呤及其盐的多晶型物 |
| CN110312721A (zh) | 2016-11-29 | 2019-10-08 | 显莎制药公司 | 墨蝶呤的多晶型物 |
| BR112020003865A8 (pt) | 2017-09-01 | 2022-08-16 | Censa Pharmaceuticals Inc | Composições farmacêuticas compreendendo sepiapterina e seus usos |
| US11617752B2 (en) | 2018-05-30 | 2023-04-04 | Ptc Therapeutics Mp, Inc. | Methods for increasing sepiapterin plasma exposure |
| BR112020024329A2 (pt) | 2018-05-30 | 2021-02-23 | Ptc Therapeutics Mp, Inc. | composições e métodos para aumentar exposição de plasma de tetra-hidrobiopterin |
| WO2020249507A1 (en) | 2019-06-11 | 2020-12-17 | Indena S.P.A. | Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it |
| EP3797834A1 (en) | 2019-09-25 | 2021-03-31 | Sanofi Mature IP | Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent |
| EP3808345A1 (en) | 2019-10-15 | 2021-04-21 | Sanofi Mature IP | Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766635A (en) * | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
| FR2722191B1 (fr) * | 1994-07-08 | 1996-08-23 | Rhone Poulenc Rorer Sa | Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle |
| DE4425978C1 (de) * | 1994-07-22 | 1995-11-23 | Karlsruhe Forschzent | Verfahren zur Herstellung keramischer Mikrostrukturen |
| MA23823A1 (fr) * | 1995-03-27 | 1996-10-01 | Aventis Pharma Sa | Nouveaux taxoides, leur preparation et les compositions qui les contiennent |
| FR2745814B1 (fr) * | 1996-03-06 | 1998-04-03 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2771092B1 (fr) | 1997-11-18 | 1999-12-17 | Rhone Poulenc Rorer Sa | Procede de preparation de derives de la classe des taxoides |
| EP0982027A1 (en) * | 1998-08-17 | 2000-03-01 | Aventis Pharma S.A. | Taxoid derivatives for treating abnormal cell proliferation of the brain |
| US6346543B1 (en) * | 1998-08-17 | 2002-02-12 | Aventis Pharma S.A. | Use of a taxoid to treat abnormal cell proliferation in the brain |
| US6136989A (en) * | 1998-12-30 | 2000-10-24 | Phytogen Life Sciences, Incorporated | Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material |
| US5969165A (en) * | 1999-01-07 | 1999-10-19 | 508037 (Nb) Inc. | Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column |
| IL144976A0 (en) * | 1999-05-17 | 2002-06-30 | Bristol Myers Squibb Co | A process for the preparation of paclitaxel |
| EP1457492B1 (en) * | 2001-11-29 | 2008-01-02 | Daiichi Sankyo Company, Limited | Crystals of taxane derivative and process for their production |
-
2003
- 2003-09-19 FR FR0311016A patent/FR2859996B1/fr not_active Expired - Lifetime
-
2004
- 2004-08-19 PE PE2004000799A patent/PE20050870A1/es not_active Application Discontinuation
- 2004-09-16 SI SI200432016T patent/SI1667986T1/sl unknown
- 2004-09-16 WO PCT/FR2004/002344 patent/WO2005028462A1/fr active Application Filing
- 2004-09-16 RS YUP-2006/0189A patent/RS20060189A/sr unknown
- 2004-09-16 UA UAA200604360A patent/UA87115C2/ru unknown
- 2004-09-16 PT PT4787385T patent/PT1667986E/pt unknown
- 2004-09-16 MX MXPA06002639A patent/MXPA06002639A/es active IP Right Grant
- 2004-09-16 HR HRP20130322TT patent/HRP20130322T1/hr unknown
- 2004-09-16 AR ARP040103329A patent/AR045667A1/es not_active Application Discontinuation
- 2004-09-16 RU RU2006113122/04A patent/RU2342373C2/ru active Protection Beyond IP Right Term
- 2004-09-16 ME MEP-117/08A patent/MEP11708A/xx unknown
- 2004-09-16 ES ES04787385T patent/ES2403149T4/es not_active Expired - Lifetime
- 2004-09-16 JP JP2006526663A patent/JP5010279B2/ja not_active Expired - Lifetime
- 2004-09-16 BR BRPI0414492A patent/BRPI0414492A8/pt not_active Application Discontinuation
- 2004-09-16 PA PA20048612401A patent/PA8612401A1/es unknown
- 2004-09-16 RS RS20060189A patent/RS54614B1/en unknown
- 2004-09-16 ME MEP-2008-117A patent/ME00054B/me unknown
- 2004-09-16 NZ NZ545835A patent/NZ545835A/en not_active IP Right Cessation
- 2004-09-16 KR KR1020067005396A patent/KR101123588B1/ko not_active Expired - Lifetime
- 2004-09-16 CN CNB200480026128XA patent/CN100429207C/zh not_active Expired - Lifetime
- 2004-09-16 EP EP04787385A patent/EP1667986B1/fr not_active Expired - Lifetime
- 2004-09-16 PL PL04787385T patent/PL1667986T3/pl unknown
- 2004-09-16 CA CA002539309A patent/CA2539309A1/fr not_active Abandoned
- 2004-09-16 AU AU2004274212A patent/AU2004274212B2/en active Active
- 2004-09-16 DK DK04787385.6T patent/DK1667986T3/da active
- 2004-09-17 MY MYPI20043787A patent/MY136668A/en unknown
- 2004-09-17 US US10/944,254 patent/US7241907B2/en active Active
- 2004-09-17 TW TW093128097A patent/TWI382022B/zh not_active IP Right Cessation
-
2006
- 2006-03-09 IL IL174240A patent/IL174240A/en active IP Right Grant
- 2006-03-15 CR CR8292A patent/CR8292A/es unknown
- 2006-03-17 TN TNP2006000086A patent/TNSN06086A1/en unknown
- 2006-03-17 MA MA28881A patent/MA28045A1/fr unknown
- 2006-03-17 ZA ZA200602255A patent/ZA200602255B/en unknown
- 2006-04-19 NO NO20061714A patent/NO335997B1/no active Protection Beyond IP Right Term
-
2013
- 2013-03-20 LU LU92172C patent/LU92172I2/fr unknown
- 2013-04-16 CY CY20131100313T patent/CY1114575T1/el unknown
- 2013-05-13 CY CY2013016C patent/CY2013016I1/el unknown
- 2013-06-07 HU HUS1300025C patent/HUS1300025I1/hu unknown
- 2013-06-13 BE BE2013C036C patent/BE2013C036I2/fr unknown
- 2013-07-04 FR FR13C0037C patent/FR13C0037I2/fr active Active
-
2015
- 2015-04-22 NO NO2015013C patent/NO2015013I1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2403149T4 (es) | Solvato acetónico de dimetoxi docetaxel y su procedimiento de preparación | |
| ES3034158T3 (en) | Novel salt of terphenyl compound | |
| ES2533710T3 (es) | Proceso para la preparación de derivados de morfolinil antraciclina | |
| ES2896101T3 (es) | Cocristales de inhibidores de SGLT2, procedimiento para su preparación y composiciones farmacéuticas de los mismos | |
| ES2762943T3 (es) | Formas de Selexipag en estado sólido | |
| ES2659549T3 (es) | Sales cristalinas de Raltegravir sódico | |
| ES2960051T3 (es) | Proceso para la producción de ozanimod | |
| EA032179B1 (ru) | Гемисульфатная соль 5,10-метилен-(6r)-тетрагидрофолиевой кислоты | |
| Zhou et al. | An effective biocompatible fluorescent probe for bisulfite detection in aqueous solution, living cells, and mice | |
| US20230020197A1 (en) | Crystal of indocyanine compound | |
| ES2645478T3 (es) | Forma cristalina anhidra de Cabazitaxel, procedimiento de preparación y composiciones farmacéuticas de la misma | |
| ES3014440T3 (en) | Method of manufacturing a pharmaceutical composition | |
| Łowicki et al. | Syntheses, structural and antimicrobial studies of a new N-allylamide of monensin A and its complexes with monovalent metal cations | |
| RU2426735C2 (ru) | Кристаллическая форма винфлунина дитартрата | |
| ES2607498T3 (es) | Peptidomiméticos que poseen actividad biológica fotocontrolada | |
| WO2018067805A1 (en) | Solid state forms of sotagliflozin | |
| ES2634243T3 (es) | Complejo de agomelatina-urea y formas cristalinas del mismo | |
| US20170327509A1 (en) | Two-photon absorbing fluorophores and method for cellular imaging using the same | |
| ES2973874T3 (es) | Formas sólidas de ceftolozano y procesos para su preparación | |
| EA022831B1 (ru) | Твердые формы {[(2s,5r,8s,11s)-5-бензил-11-(3-гуанидинопропил)-8-изопропил-7-метил-3,6,9,12,15-пентаоксо-1,4,7,10,13-пентаазациклопентадец-2-ил]уксусной кислоты} и способы их получения | |
| Ghosh et al. | Synthesis and evaluation of an imidazole derivative–fluorescein conjugate | |
| HU206359B (en) | Process for producing non-solvated "a" crystalline form of 3-/(4-cinnamyl-1-piperazinyl)-iminomethyl/-rifamycin-sv | |
| ES2974095T3 (es) | Formas de estado sólido de linaclotida | |
| HK1093340B (en) | Dimethoxy docetaxel acetone solvate et method for the preparation thereof | |
| RO133946B1 (ro) | Procedee de preparare şi utilizare ale noilor forme cristaline ale 6-(3-metil-5-nitroimidazol-4-il)sulfanil-9h-pu rinei |